Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
309M
-
Number of holders
-
5
-
Total 13F shares, excl. options
-
2.04M
-
Shares change
-
+384K
-
Total reported value, excl. options
-
$29M
-
Value change
-
+$5.45M
-
Number of buys
-
2
-
Number of sells
-
-1
-
Price
-
$14.19
Significant Holders of AMICUS THERAPEUTICS, INC. - Common Stock, par value $0.01 per share (FOLD) as of Q4 2023
5 filings reported holding FOLD - AMICUS THERAPEUTICS, INC. - Common Stock, par value $0.01 per share as of Q4 2023.
AMICUS THERAPEUTICS, INC. - Common Stock, par value $0.01 per share (FOLD) has 5 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.04M shares
of 309M outstanding shares and own 0.66% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (28.5M shares), PERCEPTIVE ADVISORS LLC (28.1M shares), Avoro Capital Advisors LLC (27.4M shares), BlackRock Inc. (23M shares), JPMORGAN CHASE & CO (17.8M shares), WELLINGTON MANAGEMENT GROUP LLP (15.2M shares), Redmile Group, LLC (14.8M shares), MORGAN STANLEY (13.3M shares), STATE STREET CORP (13.2M shares), and WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (11.6M shares).
This table shows the top 5 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.